Biopharmaceuticals Market (Monoclonal Antibodies, Recombinant Proteins, Granulocyte Colony-Stimulating Factor, Interferon, Recombinant Human Insulin, Erythropoietin, Vaccines, Growth Hormones, Purified Proteins; Oncology, Inflammatory Infectious Diseases, Metabolic Disorders, Cardiovascular Diseases; North America, Europe, Asia-Pacific, and RoW) Global Scenario, Market Size, Outlook, Trend and Forecast, 2015-2024
Global Biopharmaceuticals Market is estimated to reach $405 billion by 2024; growing at a CAGR of 9.3% from 2016 to 2024. Biopharmaceuticals are proteins and nucleic acids that are produced by means of recombinant DNA techniques, purification processes, and hybridoma techniques. The production of these medical drugs mainly involves transgenic organisms, largely plants, and animals that have been genetically modified to produce drugs. Biopharmaceuticals are basically proteins in nature comprising of antibodies and nucleic acids and are used for vivo diagnostic purpose and therapeutic. They aid in the treatment of several chronic diseases including metabolic, cardiovascular, neurological, cancer and other intermittent diseases for which no other treatments are available at present.
Advanced technologies, improved efficiency as compared to conventional drugs, and increasing prevalence of autoimmune diseases and cancer are the major factors driving the growth of the global biopharmaceuticals market. Additionally, increasing government investments for the development of advanced products, and growing preference of herbal medicines could offer future scope in the coming years. Though, possibility of adverse effects and presence of low priced biosimilars could limit the adoption among end users.
The global biopharmaceuticals market has been categorized into type, therapeutic application, and geography. Type segment is bifurcated into purified proteins, interferon, monoclonal antibodies, granulocyte colony-stimulating factor (G-CSF), recombinant proteins, recombinant human insulin, erythropoietin, vaccines, growth hormones, and others. Therapeutic application is further segmented into oncology, metabolic disorders, inflammatory infectious diseases, cardiovascular diseases, and others.
By geography, the biopharmaceuticals market has been categorized into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers Germany, UK, France, Italy, and others. Asia-Pacific covers India, Japan, China, and others. Rest of the World (RoW) covers South America, Middle East, and Africa.
The key players in the global biopharmaceuticals market include Eli Lilly and Company, Biocon Ltd, Roche Holding AG, Bayer AG, Johnson & Johnson, Inc, Genentech, Inc., Abbott Laboratories, Ranbaxy Laboratories Ltd., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, and Biogen, Inc, among others.
The key takeaways from the report
Type Segments
Advanced technologies, improved efficiency as compared to conventional drugs, and increasing prevalence of autoimmune diseases and cancer are the major factors driving the growth of the global biopharmaceuticals market. Additionally, increasing government investments for the development of advanced products, and growing preference of herbal medicines could offer future scope in the coming years. Though, possibility of adverse effects and presence of low priced biosimilars could limit the adoption among end users.
The global biopharmaceuticals market has been categorized into type, therapeutic application, and geography. Type segment is bifurcated into purified proteins, interferon, monoclonal antibodies, granulocyte colony-stimulating factor (G-CSF), recombinant proteins, recombinant human insulin, erythropoietin, vaccines, growth hormones, and others. Therapeutic application is further segmented into oncology, metabolic disorders, inflammatory infectious diseases, cardiovascular diseases, and others.
By geography, the biopharmaceuticals market has been categorized into North America, Europe, Asia-Pacific, and Rest of the World (RoW). The U.S., Canada, and Mexico are covered under North America wherein Europe covers Germany, UK, France, Italy, and others. Asia-Pacific covers India, Japan, China, and others. Rest of the World (RoW) covers South America, Middle East, and Africa.
The key players in the global biopharmaceuticals market include Eli Lilly and Company, Biocon Ltd, Roche Holding AG, Bayer AG, Johnson & Johnson, Inc, Genentech, Inc., Abbott Laboratories, Ranbaxy Laboratories Ltd., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, and Biogen, Inc, among others.
The key takeaways from the report
- The report will provide detailed analysis of Biopharmaceuticals Market with respect to major segments such as type, and therapeutic application
- The report will include the qualitative and quantitative analysis with market estimation over 2015-2024 and compound annual growth rate (CAGR) between 2016 and 2024
- Comprehensive analysis of market dynamics including factors and opportunities will be provided in the report
- An exhaustive regional analysis of Biopharmaceuticals Market has been included in the report
- Profile of the key players of the Biopharmaceuticals Market will be provided, which include key financials, product & services, new developments and business strategies
Type Segments
- Purified Proteins
- Interferon
- Monoclonal Antibodies
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Recombinant Proteins
- Recombinant Human Insulin
- Erythropoietin
- Vaccines
- Growth Hormones
- Other Types
- Oncology
- Metabolic Disorders
- Inflammatory Infectious Diseases
- Cardiovascular Diseases
- Other Therapeutic Applications
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Others
- Asia-Pacific
- India
- Japan
- China
- Others
- RoW
- South America
- Middle East
- Africa
CHAPTER 1 PREFIX
1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 In-house Data Modeling
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OUTLINE
3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Value Chain Analysis
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Impact Analysis
3.4.2 Restraints
3.4.2.1 Impact Analysis
3.4.3 Opportunities
3.5 Porter’s five forces analysis
3.5.1 Factors Impact Analysis
CHAPTER 4 BIOPHARMACEUTICALS MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
4.1 Overview
4.2 Monoclonal Antibodies
4.2.1 Current Trend and Analysis
4.2.2 Market Size and Forecast
4.3 Recombinant Proteins
4.3.1 Current Trend and Analysis
4.3.2 Market Size and Forecast
4.4 Granulocyte Colony-Stimulating Factor (G-CSF)
4.4.1 Current Trend and Analysis
4.4.2 Market Size and Forecast
4.5 Interferon
4.5.1 Current Trend and Analysis
4.5.2 Market Size and Forecast
4.6 Recombinant Human Insulin
4.6.1 Current Trend and Analysis
4.6.2 Market Size and Forecast
4.7 Erythropoietin
4.7.1 Current Trend and Analysis
4.7.2 Market Size and Forecast
4.8 Vaccines
4.8.1 Current Trend and Analysis
4.8.2 Market Size and Forecast
4.9 Growth Hormones
4.9.1 Current Trend and Analysis
4.9.2 Market Size and Forecast
4.10 Purified Proteins
4.10.1 Current Trend and Analysis
4.10.2 Market Size and Forecast
4.11 Other Types
4.11.1 Current Trend and Analysis
4.11.2 Market Size and Forecast
CHAPTER 5 BIOPHARMACEUTICALS MARKET BY THERAPEUTIC APPLICATION: MARKET SIZE AND FORECAST, 2015 – 2024
5.1 Overview
5.2 Oncology
5.2.1 Current Trend and Analysis
5.2.2 Market Size and Forecast
5.3 Inflammatory Infectious Diseases
5.3.1 Current Trend and Analysis
5.3.2 Market Size and Forecast
5.4 Metabolic Disorders
5.4.1 Current Trend and Analysis
5.4.2 Market Size and Forecast
5.5 Cardiovascular Diseases
5.5.1 Current Trend and Analysis
5.5.2 Market Size and Forecast
5.6 Other Therapeutic Applications
5.6.1 Current Trend and Analysis
5.6.2 Market Size and Forecast
CHAPTER 6 E-CLINICAL SOLUTION SOFTWARE MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024
6.1 Overview
6.2 North America
6.2.1 Current Trend and Analysis
6.2.2 Market Size and Forecast
6.2.3 US
6.2.3.1 Market Size and Forecast
6.2.4 Canada
6.2.4.1 Market Size and Forecast
6.2.5 Mexico
6.2.5.1 Market Size and Forecast
6.3 Europe
6.3.1 Current Trend and Analysis
6.3.2 Market Size and Forecast
6.3.3 UK
6.3.3.1 Market Size and Forecast
6.3.4 Germany
6.3.4.1 Market Size and Forecast
6.3.5 France
6.3.5.1 Market Size and Forecast
6.3.6 Italy
6.3.6.1 Market Size and Forecast
6.3.6 Others
6.3.6.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Current Trend and Analysis
6.4.2 Market Size and Forecast
6.4.3 Japan
6.4.3.1 Market Size and Forecast
6.4.4 China
6.4.4.1 Market Size and Forecast
6.4.5 India
6.4.5.1 Market Size and Forecast
6.4.6 Others
6.4.6.1 Market Size and Forecast
6.5 RoW
6.5.1 Current Trend and Analysis
6.5.2 Market Size and Forecast
6.5.3 Middle East
6.5.3.1 Market Size and Forecast
6.5.4 South America
6.5.4.1 Market Size and Forecast
6.5.5 Africa
6.5.5.1 Market Size and Forecast
CHAPTER 7 COMPANY PROFILES
7.1 Roche Holding AG
7.2 Bayer AG
7.3 Abbott Laboratories
7.4 Biocon Ltd
7.5 Eli Lilly and Company
7.6 Ranbaxy Laboratories Ltd.
7.7 Pfizer Inc.
7.8 Novartis AG
7.9 Genentech, Inc.
7.10 Johnson & Johnson, Inc
1.1 Market Scope
1.2 Report Description
1.3 Research Methodology
1.3.1 Primary Research
1.3.2 Secondary Research
1.3.3 In-house Data Modeling
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OUTLINE
3.1 Market Inclination, Trend, Outlook and Viewpoint
3.2 Market Share Analysis: Company’s Competitive Scenario
3.3 Value Chain Analysis
3.4 Market Dynamics
3.4.1 Drivers
3.4.1.1 Impact Analysis
3.4.2 Restraints
3.4.2.1 Impact Analysis
3.4.3 Opportunities
3.5 Porter’s five forces analysis
3.5.1 Factors Impact Analysis
CHAPTER 4 BIOPHARMACEUTICALS MARKET BY TYPE: MARKET SIZE AND FORECAST, 2015 – 2024
4.1 Overview
4.2 Monoclonal Antibodies
4.2.1 Current Trend and Analysis
4.2.2 Market Size and Forecast
4.3 Recombinant Proteins
4.3.1 Current Trend and Analysis
4.3.2 Market Size and Forecast
4.4 Granulocyte Colony-Stimulating Factor (G-CSF)
4.4.1 Current Trend and Analysis
4.4.2 Market Size and Forecast
4.5 Interferon
4.5.1 Current Trend and Analysis
4.5.2 Market Size and Forecast
4.6 Recombinant Human Insulin
4.6.1 Current Trend and Analysis
4.6.2 Market Size and Forecast
4.7 Erythropoietin
4.7.1 Current Trend and Analysis
4.7.2 Market Size and Forecast
4.8 Vaccines
4.8.1 Current Trend and Analysis
4.8.2 Market Size and Forecast
4.9 Growth Hormones
4.9.1 Current Trend and Analysis
4.9.2 Market Size and Forecast
4.10 Purified Proteins
4.10.1 Current Trend and Analysis
4.10.2 Market Size and Forecast
4.11 Other Types
4.11.1 Current Trend and Analysis
4.11.2 Market Size and Forecast
CHAPTER 5 BIOPHARMACEUTICALS MARKET BY THERAPEUTIC APPLICATION: MARKET SIZE AND FORECAST, 2015 – 2024
5.1 Overview
5.2 Oncology
5.2.1 Current Trend and Analysis
5.2.2 Market Size and Forecast
5.3 Inflammatory Infectious Diseases
5.3.1 Current Trend and Analysis
5.3.2 Market Size and Forecast
5.4 Metabolic Disorders
5.4.1 Current Trend and Analysis
5.4.2 Market Size and Forecast
5.5 Cardiovascular Diseases
5.5.1 Current Trend and Analysis
5.5.2 Market Size and Forecast
5.6 Other Therapeutic Applications
5.6.1 Current Trend and Analysis
5.6.2 Market Size and Forecast
CHAPTER 6 E-CLINICAL SOLUTION SOFTWARE MARKET BY GEOGRAPHY: MARKET SIZE AND FORECAST, 2015 – 2024
6.1 Overview
6.2 North America
6.2.1 Current Trend and Analysis
6.2.2 Market Size and Forecast
6.2.3 US
6.2.3.1 Market Size and Forecast
6.2.4 Canada
6.2.4.1 Market Size and Forecast
6.2.5 Mexico
6.2.5.1 Market Size and Forecast
6.3 Europe
6.3.1 Current Trend and Analysis
6.3.2 Market Size and Forecast
6.3.3 UK
6.3.3.1 Market Size and Forecast
6.3.4 Germany
6.3.4.1 Market Size and Forecast
6.3.5 France
6.3.5.1 Market Size and Forecast
6.3.6 Italy
6.3.6.1 Market Size and Forecast
6.3.6 Others
6.3.6.1 Market Size and Forecast
6.4 Asia-Pacific
6.4.1 Current Trend and Analysis
6.4.2 Market Size and Forecast
6.4.3 Japan
6.4.3.1 Market Size and Forecast
6.4.4 China
6.4.4.1 Market Size and Forecast
6.4.5 India
6.4.5.1 Market Size and Forecast
6.4.6 Others
6.4.6.1 Market Size and Forecast
6.5 RoW
6.5.1 Current Trend and Analysis
6.5.2 Market Size and Forecast
6.5.3 Middle East
6.5.3.1 Market Size and Forecast
6.5.4 South America
6.5.4.1 Market Size and Forecast
6.5.5 Africa
6.5.5.1 Market Size and Forecast
CHAPTER 7 COMPANY PROFILES
7.1 Roche Holding AG
7.2 Bayer AG
7.3 Abbott Laboratories
7.4 Biocon Ltd
7.5 Eli Lilly and Company
7.6 Ranbaxy Laboratories Ltd.
7.7 Pfizer Inc.
7.8 Novartis AG
7.9 Genentech, Inc.
7.10 Johnson & Johnson, Inc
